Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors
Nuvectis Pharma announced that its partner Haisco received the first global marketing approval for Ciprocopan (NXP100) from China's NMPA for treatment-naive PNH patients. The approval was supported by a Phase 3 head-to-head study showing superiority over Soliris, with 59.5% of patients reaching hemoglobin targets compared to 8.3% for the standard of care.
Key figures
- Drug Name
- Ciprocopan (NXP100)
- Phase Of Trial
- Phase 3
- Hb increase vs soliris
- 5.0 g/dL vs 2.2 g/dL
- Transfusion free vs soliris
- 94.6% vs 69.4%
- Hb target response vs soliris
- 59.5% vs 8.3%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.